187 related articles for article (PubMed ID: 7684597)
21. Prognostic factors in metastatic non-seminomatous germ cell tumours: the Medical Research Council studies.
Mead GM; Stenning SP
Eur Urol; 1993; 23(1):196-200; discussion 201. PubMed ID: 7682951
[TBL] [Abstract][Full Text] [Related]
22. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
23. The present and future of serum diagnostic tests for testicular germ cell tumours.
Murray MJ; Huddart RA; Coleman N
Nat Rev Urol; 2016 Dec; 13(12):715-725. PubMed ID: 27754472
[TBL] [Abstract][Full Text] [Related]
24. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
Neumann A; Keller T; Jocham D; Doehn C
Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors.
Mego M; Rejlekova K; Reckova M; Sycova-Mila Z; Obertova J; Rajec J; Mardiak J
Neoplasma; 2009; 56(5):398-403. PubMed ID: 19580341
[TBL] [Abstract][Full Text] [Related]
27. Does extragonadal presentation impart a worse prognosis to abdominal germ-cell tumours?
McAleer JJ; Nicholls J; Horwich A
Eur J Cancer; 1992; 28A(4-5):825-8. PubMed ID: 1381929
[TBL] [Abstract][Full Text] [Related]
28. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
Toner GC; Geller NL; Tan C; Nisselbaum J; Bosl GJ
Cancer Res; 1990 Sep; 50(18):5904-10. PubMed ID: 1697503
[TBL] [Abstract][Full Text] [Related]
29. The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time--I. Theoretical basis and practical application.
Price P; Hogan SJ; Horwich A
Eur J Cancer; 1990 Apr; 26(4):450-3. PubMed ID: 1694086
[TBL] [Abstract][Full Text] [Related]
30. Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.
Seckl MJ; Rustin GJ; Bagshawe KD
Br J Cancer; 1990 Jun; 61(6):916-8. PubMed ID: 1695522
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
Aass N; Klepp O; Cavallin-Stahl E; Dahl O; Wicklund H; Unsgaard B; Baldetorp L; Ahlström S; Fosså SD
J Clin Oncol; 1991 May; 9(5):818-26. PubMed ID: 1707957
[TBL] [Abstract][Full Text] [Related]
32. Elevated lactate dehydrogenase isoenzyme 1 as a tumour marker in patients with germ cell testicular tumours.
Winkle DC; Clague AE; Gardiner RA
Aust N Z J Surg; 1988 Sep; 58(9):737-41. PubMed ID: 2854968
[TBL] [Abstract][Full Text] [Related]
33. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
34. [Clinical presentation of testicular germinal cancer].
Fernández Gómez JM; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; Escaf Barmadah S; García Rodríguez J; Pérez García FJ; Rodríguez Faba O; Jalón Monzón A
Arch Esp Urol; 2002 Oct; 55(8):915-22. PubMed ID: 12455282
[TBL] [Abstract][Full Text] [Related]
35. Tumor markers in patients with non-seminomatous germ cell tumors of the testis.
Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
Oncodev Biol Med; 1981; 2(1-2):117-28. PubMed ID: 6170952
[TBL] [Abstract][Full Text] [Related]
36. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
Massard C; Kramar A; Beyer J; Hartmann JT; Lorch A; Pico JL; Rosti G; Droz JP; Fizazi K
Ann Oncol; 2013 Feb; 24(2):322-328. PubMed ID: 23104726
[TBL] [Abstract][Full Text] [Related]
37. [Plasma lactate dehydrogenase and its isoenzymes in nonseminomatous germ cell tumors of the testis].
Canal P; Villeneuve G; Bugat R; Armand JP; Soula G
Pathol Biol (Paris); 1984 Apr; 32(4):245-50. PubMed ID: 6201806
[TBL] [Abstract][Full Text] [Related]
38. Metastatic non-seminomatous germ cell tumour and dermatomyositis.
Barker RA; Currie DC; Horwich A; Spiro SG
Postgrad Med J; 1990 Jan; 66(771):59-60. PubMed ID: 1693426
[TBL] [Abstract][Full Text] [Related]
39. Serum tumor markers in patients with metastatic germ cell tumors of the testis. A 10-year experience.
Bosl GJ; Geller NL; Cirrincione C; Nisselbaum J; Vugrin D; Whitmore WF; Golbey RB
Am J Med; 1983 Jul; 75(1):29-35. PubMed ID: 6190398
[TBL] [Abstract][Full Text] [Related]
40. The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis.
Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
Oncodev Biol Med; 1981; 2(1-2):129-34. PubMed ID: 6170953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]